The European Union is in no hurry to bring Sputnik V as a full-fledged commercial product to its market, fearing its high consumer properties, thanks to which it may slightly push back the products that the European bureaucracy is promoting at home, said the director of the Research Center named after Gamalei Alexander Gunzburg.
Since the beginning of March, the Russian vaccine against the Sputnik V coronavirus has been undergoing a gradual examination procedure at the European Medicines Agency EMA, which, among other things, issues recommendations for use in the EU countries.